OTCMKTS:TBET

Tibet Pharmaceuticals Competitors

$0.01
+0.00 (+4.76 %)
(As of 06/11/2021 03:50 PM ET)
Add
Compare
Today's Range
$0.01
$0.02
50-Day Range
$0.01
$0.03
52-Week Range
$0.00
$0.10
Volume160,000 shs
Average Volume64,709 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta8.99

Tibet Pharmaceuticals (OTCMKTS:TBET) Vs. NEVPF, AKAOQ, ACUS, ADTX, AOLS, and AFFY

Should you be buying TBET stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Tibet Pharmaceuticals, including Abliva AB (publ) (NEVPF), Achaogen (AKAOQ), Acusphere (ACUS), ADiTx Therapeutics (ADTX), Aeolus Pharmaceuticals (AOLS), and Affymax (AFFY).

Abliva AB (publ) (OTCMKTS:NEVPF) and Tibet Pharmaceuticals (OTCMKTS:TBET) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a summary of current recommendations for Abliva AB (publ) and Tibet Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abliva AB (publ)0000N/A
Tibet Pharmaceuticals0000N/A

Valuation and Earnings

This table compares Abliva AB (publ) and Tibet Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abliva AB (publ)$10,000.003,163.26$-8,150,000.00N/AN/A
Tibet PharmaceuticalsN/AN/AN/AN/AN/A

Tibet Pharmaceuticals has lower revenue, but higher earnings than Abliva AB (publ).

Profitability

This table compares Abliva AB (publ) and Tibet Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abliva AB (publ)N/A-54.20%-49.31%
Tibet PharmaceuticalsN/AN/AN/A

Summary

Tibet Pharmaceuticals beats Abliva AB (publ) on 2 of the 3 factors compared between the two stocks.

Tibet Pharmaceuticals (OTCMKTS:TBET) and Achaogen (OTCMKTS:AKAOQ) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Earnings & Valuation

This table compares Tibet Pharmaceuticals and Achaogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tibet PharmaceuticalsN/AN/AN/AN/AN/A
Achaogen$8.73 million0.14$-186,510,000.00N/AN/A

Tibet Pharmaceuticals has higher earnings, but lower revenue than Achaogen.

Profitability

This table compares Tibet Pharmaceuticals and Achaogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tibet PharmaceuticalsN/AN/AN/A
AchaogenN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for Tibet Pharmaceuticals and Achaogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tibet Pharmaceuticals0000N/A
Achaogen0000N/A

Volatility & Risk

Tibet Pharmaceuticals has a beta of 8.99, indicating that its stock price is 799% more volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.81, indicating that its stock price is 181% less volatile than the S&P 500.

Acusphere (OTCMKTS:ACUS) and Tibet Pharmaceuticals (OTCMKTS:TBET) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations.

Risk & Volatility

Acusphere has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. Comparatively, Tibet Pharmaceuticals has a beta of 8.99, suggesting that its stock price is 799% more volatile than the S&P 500.

Valuation & Earnings

This table compares Acusphere and Tibet Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Acusphere and Tibet Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Acusphere and Tibet Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Tibet Pharmaceuticals0000N/A

Summary

Tibet Pharmaceuticals beats Acusphere on 1 of the 1 factors compared between the two stocks.

Tibet Pharmaceuticals (OTCMKTS:TBET) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Valuation and Earnings

This table compares Tibet Pharmaceuticals and ADiTx Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tibet PharmaceuticalsN/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/A$-9,150,000.00N/AN/A

Profitability

This table compares Tibet Pharmaceuticals and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tibet PharmaceuticalsN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Tibet Pharmaceuticals and ADiTx Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tibet Pharmaceuticals0000N/A
ADiTx Therapeutics00103.00

Summary

ADiTx Therapeutics beats Tibet Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Aeolus Pharmaceuticals (OTCMKTS:AOLS) and Tibet Pharmaceuticals (OTCMKTS:TBET) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Risk and Volatility

Aeolus Pharmaceuticals has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500. Comparatively, Tibet Pharmaceuticals has a beta of 8.99, suggesting that its stock price is 799% more volatile than the S&P 500.

Profitability

This table compares Aeolus Pharmaceuticals and Tibet Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aeolus PharmaceuticalsN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/A

Earnings and Valuation

This table compares Aeolus Pharmaceuticals and Tibet Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aeolus PharmaceuticalsN/AN/AN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Aeolus Pharmaceuticals and Tibet Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aeolus Pharmaceuticals0000N/A
Tibet Pharmaceuticals0000N/A

Summary

Tibet Pharmaceuticals beats Aeolus Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Tibet Pharmaceuticals (OTCMKTS:TBET) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Affymax and Tibet Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Tibet Pharmaceuticals0000N/A

Risk and Volatility

Affymax has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, Tibet Pharmaceuticals has a beta of 8.99, suggesting that its share price is 799% more volatile than the S&P 500.

Valuation and Earnings

This table compares Affymax and Tibet Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Affymax and Tibet Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Tibet PharmaceuticalsN/AN/AN/A

Summary

Tibet Pharmaceuticals beats Affymax on 1 of the 1 factors compared between the two stocks.


Tibet Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abliva AB (publ) logo
NEVPF
Abliva AB (publ)
0.5$0.12+16.9%$0.00$10,000.00-2.35Upcoming Earnings
Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.03+14.0%$0.00$8.73 million0.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.03+0.0%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.7$2.90+0.7%$0.00N/A0.00Increase in Short Interest
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01+27.7%$0.00N/A0.00High Trading Volume
Decrease in Short Interest
Gap Down
Affymax logo
AFFY
Affymax
0.6$0.06+0.0%$0.00N/A0.00Gap Up
Akari Therapeutics logo
AKTX
Akari Therapeutics
1.4$1.78+1.1%$0.00N/A-3.02Upcoming Earnings
AKRXQ
Akorn
0.1$0.03+0.7%$0.00$682.43 million-0.01
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.08+0.1%$0.00N/A0.00Increase in Short Interest
AOXG
Aoxing Pharmaceutical
0.5$0.01+0.0%$0.00N/A0.00Increase in Short Interest
Gap Up
ARYX
ARYx Therapeutics
0.0$0.02+25.4%$0.00N/A0.00Gap Up
AHROQ
AtheroNova
0.0$0.01+150.0%$0.00N/A0.00High Trading Volume
Gap Down
Bayer Aktiengesellschaft logo
BAYRY
Bayer Aktiengesellschaft
1.2$16.26+0.3%$0.00$47.29 billion-5.89
BSPM
Biostar Pharmaceuticals
0.0$0.12+65.7%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07+0.0%$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.04+25.3%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25+0.8%$0.00$9.93 million8.40
DDXSQ
Diadexus
0.0$0.00+0.0%$0.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01+11.0%$0.00N/A0.00Increase in Short Interest
Gap Up
ERBA
ERBA Diagnostics
0.8$0.04+14.3%$0.00N/A0.00Gap Up
FTCY
Global Future City
0.5$0.05+1.8%$0.00N/A0.00High Trading Volume
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.45+6.9%$0.00N/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.00+11.1%$0.00N/A0.00Increase in Short Interest
Gap Up
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$6.28+19.3%$0.00$110,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.62+2.6%$0.00N/A0.00Decrease in Short Interest
Gap Down
IPAH
Interpharm
0.2$0.00+100.0%$0.00N/A0.00Gap Down
IRBS
IR Biosciences
0.0$0.00+50.0%$0.00N/A0.00High Trading Volume
Gap Down
MBVXQ
MabVax Therapeutics
0.0$0.02+8.7%$0.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.00+0.0%$0.00N/A0.00
MYRX
Myrexis
0.5$0.05+0.0%$0.00N/A0.00Decrease in Short Interest
Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00+600.0%$0.00N/A0.00Gap Down
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.13+9.7%$0.00N/A0.00Increase in Short Interest
PZRXQ
PhaseRx
0.2$0.02+44.3%$0.00N/A0.00Gap Up
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.04+64.5%$0.00N/A0.00News Coverage
Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.04+13.4%$0.00N/A0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.07+38.9%$0.00N/A0.00Increase in Short Interest
Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02+0.0%$0.00N/A0.00Increase in Short Interest
Shiseido logo
SSDOY
Shiseido
1.0$74.15+0.2%$0.00$8.63 billion-218.09Increase in Short Interest
Sio Gene Therapies logo
SIOX
Sio Gene Therapies
1.6$2.49+1.6%$0.00N/A-2.96Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00+100.0%$0.00N/A0.00Gap Up
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01+66.7%$0.00N/A0.00Gap Down
SUWN
Sunwin Stevia International
0.5$0.05+14.4%$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.02+1.3%$0.00N/A0.00Decrease in Short Interest
SYNI
Synvista Therapeutics
0.0$0.00+0.0%$0.00N/A0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.02+139.3%$0.00N/A0.00Gap Down
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.03+27.8%$0.00N/A0.00Gap Up
TPIY
Tianyin Pharmaceutical
0.6$0.00+0.0%$0.00N/A0.00High Trading Volume
Tiziana Life Sciences logo
TLSA
Tiziana Life Sciences
1.2$2.49+3.2%$0.00N/A0.00Upcoming Earnings
Decrease in Short Interest
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.09+0.2%$0.00$6.81 million-4.56Decrease in Short Interest
Gap Up
VOQP
VioQuest Pharmaceuticals
0.0$0.01+1.2%$0.00N/A0.00
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.